How Long Does Ketamine Treatment Stay in Your System: A Guide to Spravato Detection Windows and Doctor’s Notes

If you’re receiving Spravato treatment for treatment-resistant depression, one of the most pressing concerns you may face is how long ketamine stays in your system, and what happens if you’re required to take a drug test. Understanding ketamine treatment detection windows is essential for any patient navigating workplace drug screening, medical procedures, or legal situations while undergoing therapeutic ketamine care.

Spravato (esketamine) is an FDA-approved nasal spray used to treat depression when an oral antidepressant alone hasn’t been enough. While this treatment can provide rapid relief of severe depression symptoms, the fact that esketamine is metabolized similarly to ketamine means it can show up on certain drug tests. This blog breaks down exactly how long ketamine stays in different test types, what factors affect detection duration, the common mistakes patients make, and what medical documentation you should have in place to protect yourself.

Key Takeaways

• Urine tests can detect ketamine for 3 to 14 days after treatment, depending on lab sensitivity and metabolites tested.
• Blood tests detect ketamine for 24 to 48 hours post-administration.
• Hair follicle tests can identify ketamine use for up to 90 days or longer.
• Saliva tests can detect ketamine for up to 48 hours.
• Medical documentation from healthcare providers is recommended for drug tests and protects patients in workplace testing scenarios.
• Detection windows vary with dosage, frequency of use, metabolism, and testing sensitivity.

Understanding Spravato Detection Windows

Spravato is the brand name for esketamine, the S-enantiomer of racemic ketamine. Unlike street ketamine or IV ketamine used in medical settings for anesthesia, Spravato is specifically designed as a nasal spray form of ketamine to treat depression, particularly treatment-resistant depression and major depressive disorder, when combined with an oral antidepressant. Spravato is a Schedule III controlled substance under the Controlled Substances Act and must be administered under medical supervision in a certified clinic.

When you take ketamine via the Spravato nasal spray, your body processes ketamine rapidly. The drug reaches peak plasma concentration within approximately 20 to 40 minutes, with a bioavailability of about 48% through intranasal delivery. From there, the body processes esketamine in the liver, primarily via CYP2B6 and CYP3A4, converting it into its major active metabolite, norketamine. These ketamine metabolites undergo further transformation, including hydroxylation and glucuronidation, before being excreted primarily through urine (over 78%) and a small fraction through feces.

Spravato has a mean terminal half-life of 7 to 12 hours. The half-life of ketamine itself is approximately 2.5 to 3 hours for the initial rapid elimination phase. This means that ketamine is usually eliminated from the body within 10 to 15 hours after a single therapeutic dose. However, metabolites remain detectable for significantly longer, which is where most drug-screening concerns arise. Patients comparing treatment options often look for trusted ketamine therapy clinics that provide supervised care, clear treatment protocols, and guidance around medication-related concerns.

Detection Timelines by Test Type

Different tests can detect ketamine and its metabolites over varying windows. The table below summarizes what current evidence tells us:

Test Type	Detection Window	Notes
Urine	3–14 days	Ketamine is detectable in urine for 3 to 5 days; norketamine can be detected in urine for up to 14 days with sensitive LC-MS/MS methods. Standard cutoff screens (~25 ng/mL) typically detect parent drug or metabolite for about 2–5 days.
Blood	24–48 hours	Ketamine is detectable in blood for 24 to 48 hours. Parent drug levels drop quickly after the first few hours post-dose.
Saliva	Up to 48 hours	Saliva tests can detect ketamine for up to 48 hours. Less commonly used in workplace settings.
Hair	Up to 90 days	Hair tests can detect ketamine for up to 90 days, and sometimes longer, depending on hair length and lab thresholds. Advanced methods can detect levels as low as 0.01 ng/mg in hair follicles.

Urine tests are the most commonly used in workplace and medical settings. Most standard drug tests, including standard 5-panel drug tests, do not include ketamine. Ketamine is not typically included in standard drug screenings. Specialized tests are required to detect ketamine, such as expanded toxicology panels that specifically target arylcyclohexylamine compounds.

When comparing single-dose vs. regular treatment detection windows, the differences matter. For a single Spravato session, the drug remains detectable in blood for roughly 12–24 hours and in urine samples for approximately 2–5 days using standard methods. For patients on maintenance treatment (weekly or biweekly sessions), metabolites like norketamine can accumulate, and norketamine metabolites can be detected for much longer than ketamine itself. Ketamine can remain detectable in the system for several days to weeks under these circumstances.

IV ketamine effects last 15 to 30 minutes, while IM ketamine effects begin in about 4 minutes. Regardless of administration route, the metabolic elimination pathways are similar, and metabolite detection timelines overlap significantly across routes.

Factors That Affect Spravato Detection Duration

Several factors affect how long ketamine stays in your system after Spravato treatment. No two patients will have identical detection windows, and understanding these variables helps you plan around upcoming drug screening events. For patients managing anxiety alongside depression, understanding how ketamine therapy helps in anxiety recovery can also make it easier to discuss treatment expectations, frequency, and follow-up care with a provider.

• Dosage and frequency of treatment are among the most significant variables. Higher doses of ketamine take longer to leave the system. Higher doses and more frequent administration prolong metabolic clearance. Frequent use can cause ketamine to accumulate in the body, extending detection windows for both the parent drug and its metabolites.
• Metabolism, age, and genetics play a central role. Metabolism speed varies by age, health, and genetics. Elderly individuals tend to have higher peak concentrations and slower clearance. Because esketamine is metabolized by CYP2B6 and CYP3A4, genetic variants in these enzymes or interactions with other drugs can significantly slow or accelerate its elimination.
• Liver function significantly affects how long ketamine stays in the system. Patients with moderate hepatic impairment show increased drug exposure and a longer half-life. Similarly, liver and kidney function affect the speed of ketamine elimination: while liver function has a more modest effect, impaired renal function can marginally prolong metabolite excretion in urine.
• Body composition and body weight matter as well. Esketamine is lipophilic, meaning more body mass (particularly body fat) may store the drug and its metabolites longer. Body composition influences distribution and clearance rates.
• Hydration levels can influence how quickly ketamine is excreted. Hydration can influence the clearance of ketamine metabolites. Well-hydrated patients tend to eliminate drugs through urine more efficiently, though this effect is modest and should not be relied upon as a primary strategy.
• Test sensitivity and lab cutoff thresholds are factors that patients often overlook. A standard immunoassay with a 25 ng/mL cutoff may not detect low-level metabolites remaining a few hours after the detection window closes. An ultra-sensitive LC-MS/MS assay used in forensic or specialized labs, however, can pick up trace amounts of dehydronorketamine for up to 10 days after a single oral dose, as demonstrated in published research.

Common Mistakes Patients Make

Many patients underestimate the complexity of ketamine detection and make avoidable errors:

• Not disclosing treatment to employers before testing: Waiting until after you’ve tested positive to explain your Spravato prescription creates unnecessary complications. Documentation from healthcare providers is recommended for drug tests; having it ready in advance streamlines the Medical Review Officer (MRO) verification process.
• Assuming most standard drug tests will never detect ketamine: While ketamine is not detected in standard 5-panel drug tests, some employers use expanded panels that specifically target ketamine. Not all workplace screenings are “standard,” and assumptions can lead to unpleasant surprises.
• Timing errors around treatment schedules and testing: Being tested within a few hours of a Spravato session means blood and urine levels are at their peak. Understanding that the drug remains in your system for a defined window allows you to schedule accordingly when possible.
• Failing to obtain or carry proper documentation: Without a prescriber’s note, prescription records, or clinic documentation, a positive result for ketamine on an expanded panel can trigger the same process as illicit drug abuse, even though your ketamine use is entirely legal and medically supervised.
• Confusing ketamine forms: Esketamine (Spravato) and racemic ketamine are chemically related, and tests that detect ketamine will generally also detect esketamine and its metabolites. Patients sometimes assume their prescribed nasal spray won’t register, but any test sensitive enough to detect ketamine metabolites will likely flag esketamine exposure as well.

Medical Documentation and Workplace Protections

Under the Americans with Disabilities Act (ADA), employees using prescription medications, including Spravato, for qualifying conditions such as treatment-resistant depression are legally protected. A drug test revealing prescribed medication cannot be the sole basis for adverse employment action. Employers must evaluate whether the employee can perform essential job functions and whether any safety concerns can be mitigated through reasonable accommodation. Because ketamine is also being studied in broader mental health care, patients may benefit from learning how ketamine therapy in addiction treatment is approached differently from recreational misuse or unsupervised drug use.

If a test result comes back positive for ketamine, the Medical Review Officer (MRO) reviews the case. With valid documentation, such as a prescription, pharmacy records, and a provider’s note, the MRO can report the result as medically explained or negative for illicit drug misuse. This process is critical for patients who have tested positive due to legitimate therapeutic ketamine treatment.

State laws vary regarding when employers can test, what they can ask, and how results are used. However, across most jurisdictions, a positive result from prescribed drug use (such as Spravato) is treated differently from illicit ketamine abuse or recreational drug use.

What documentation does New Life Wellness and Ketamine Clinic provide:

• A prescriber note identifying the patient, medical condition, dates of Spravato treatments, dosage, frequency, and whether the patient is on maintenance therapy.
• Prescription or pharmacy label verifying legitimate Spravato use.
• A pharmacology summary explaining that Spravato is esketamine, metabolized similarly to ketamine, and may produce a positive result on ketamine-specific drug tests.
• A return-to-work or treatment-day note to accommodate safety-sensitive roles, particularly for patients whose jobs involve driving, heavy machinery, or other safety-critical tasks.
• Confirmation of clinic monitoring protocols, demonstrating that Spravato is administered under medical supervision as required by prescribing guidelines, clearly distinguishing therapeutic use from drug abuse or ketamine misuse.
• A statement on expected detection windows to help patients plan around testing.

Ketamine is also studied for treating PTSD and chronic pain, and it can provide pain relief in certain medical procedures. Regardless of the indication, the distinction between legitimate medical use and recreational misuse is well-established in law. Patients who proactively communicate with their employers, provide documentation, and work with their healthcare providers are far better positioned to navigate any drug-screening situation.

Final Thoughts

For Spravato patients, understanding how long ketamine remains detectable is important when preparing for workplace drug testing, medical evaluations, or legal requirements. While ketamine itself is eliminated relatively quickly, its metabolites can remain detectable for days or even months, depending on the type of test used. Factors such as dosage, treatment frequency, metabolism, and testing methods all play a role in determining detection windows, making it essential for patients to stay informed and maintain proper medical documentation.

At New Life Wellness and Ketamine Clinic, we are committed to helping patients with ketamine therapy in Dayton, from understanding detection timelines to obtaining the documentation needed for workplace and legal situations. Whether you’re exploring Spravato treatment, nasal spray therapy, addiction treatment support, or functional medicine services, our experienced team provides personalized care tailored to your unique mental health and wellness needs. Contact us today to discover the treatment approach that’s right for you.

Frequently Asked Questions

Will Spravato show up on a standard drug test?

No. Ketamine is not detected in standard 5-panel drug tests, which typically screen for opioids, amphetamines, cocaine, PCP, and THC. Specialized tests are required to detect ketamine. However, some employers use expanded toxicology panels that include ketamine, so it’s important to know which panel your employer uses.

How long after my last Spravato treatment should I wait before a drug test?

It depends on the test type. Blood tests detect ketamine for 24 to 48 hours. Urine tests can detect ketamine for 3 to 14 days, with norketamine metabolites detectable for up to 14 days using sensitive methods. Detection windows vary with dosage and frequency of use, so patients on frequent treatment schedules should allow more time. Discuss timing with your provider for personalized guidance.

Can my employer discriminate against me for prescribed Spravato treatment?

Under the ADA, employers cannot take adverse action against employees solely because they are using legally prescribed medications for a qualifying condition like treatment-resistant depression. If you tested positive on an expanded panel, the MRO process allows you to present documentation proving your use is medically supervised. State laws provide additional protections in many jurisdictions.

Do I need to tell my employer about my ketamine treatment before a test?

You are not typically required to disclose prescription medications before a test. However, proactively informing the testing facility or MRO and having documentation ready can prevent delays and misunderstandings if a positive result occurs. Early disclosure is especially important for patients in safety-sensitive roles.

How is therapeutic ketamine different from recreational use in drug testing?

From a chemistry standpoint, tests that detect ketamine will flag both therapeutic and recreational ketamine use; the test cannot distinguish intent. The key difference is documentation. Patients receiving Spravato under medical supervision at a certified clinic have prescriptions, treatment records, and clinic monitoring protocols that clearly differentiate their use from illicit ketamine abuse or drug misuse. This documentation is what protects patients in the workplace and legal settings.